Billiontoone (NASDAQ:BLLN) Releases Quarterly Earnings Results

Billiontoone (NASDAQ:BLLN) released its quarterly earnings results on Wednesday. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.07, Briefing.com reports. The firm’s quarterly revenue was up 113.0% on a year-over-year basis.

Here are the key takeaways from Billiontoone’s conference call:

• Financial outperformance: BillionToOne reported 100% year‑over‑year revenue growth for 2025 (Q4 revenue $96.1M, +113% YoY), an annualized run‑rate of $384M, GAAP profitability for Q4 and full year, and a strong balance sheet with ~$496M cash versus ~$50M term debt.
• Product and reimbursement catalysts: The company launched expanded prenatal offerings (including the first platelet fetal‑antigen NIPT), oncology add‑ons (Northstar PGx and CH), submitted Northstar Response to MolDx, and signed an in‑network contract with UnitedHealthcare, all of which could accelerate volume and ASPs.
• Improving unit economics and margins: ASPs rose sharply (2025 ASP $495; Q4 ASP $561), COGS per test declined, gross margin reached 71.4% in Q4, and operating/adjusted EBITDA margins turned positive, reflecting higher efficiency and automation.
• Key risks and conservative assumptions: 2026 guidance ($430M–$445M) excludes potential upside from United and health‑system EMR integrations, MolDx coverage for Northstar Response is still pending, and results remain sensitive to payer coverage, mix shifts to oncology, and true‑up variability.

Billiontoone Price Performance

BLLN stock traded down $2.31 during mid-day trading on Wednesday, reaching $80.83. The company had a trading volume of 392,982 shares, compared to its average volume of 245,757. Billiontoone has a 52 week low of $66.00 and a 52 week high of $138.70. The stock’s 50 day moving average is $86.15. The company has a market capitalization of $3.70 billion and a P/E ratio of 808.30.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Stifel Nicolaus started coverage on Billiontoone in a research note on Monday, December 1st. They set a “buy” rating and a $145.00 target price for the company. Guggenheim started coverage on shares of Billiontoone in a report on Tuesday, January 6th. They issued a “buy” rating and a $120.00 price target for the company. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Billiontoone in a report on Wednesday, December 10th. Piper Sandler reaffirmed an “overweight” rating on shares of Billiontoone in a research report on Wednesday, December 10th. Finally, Wells Fargo & Company initiated coverage on Billiontoone in a report on Monday, December 1st. They set an “equal weight” rating and a $110.00 target price for the company. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Billiontoone has an average rating of “Moderate Buy” and an average target price of $135.29.

Billiontoone News Summary

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q4 results beat expectations — BillionToOne reported $0.11 EPS vs. consensus $0.04 and revenue +113% year-over-year, signaling robust top-line growth and margin improvement. GlobeNewswire: Q4 and FY2025 Results
• Positive Sentiment: Raised FY2026 revenue guidance — management now expects roughly $430M–$445M in revenue for 2026 versus a prior consensus near $356M, implying accelerated growth expectations that justify a higher valuation multiple if execution continues. GlobeNewswire: Guidance Raise
• Neutral Sentiment: Analyst/metrics write-ups — Zacks and other outlets published analysis comparing BLLN’s quarter and key metrics to estimates; useful for drill-down but not new company guidance. Zacks: Q4 Metrics vs. Estimates
• Neutral Sentiment: Earnings snapshot coverage — local/business outlets summarized the quarter; helpful context but no fresh catalysts beyond the company release. LMT Online: Q4 Snapshot
• Neutral Sentiment: Short-interest reporting appears anomalous — several reports show a “large increase” but list zero shares and NaN changes; data looks unreliable and should not be treated as a clear short-pressure signal until exchanges/clearing firms reconcile the figures.

Hedge Funds Weigh In On Billiontoone

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rossby Financial LCC bought a new position in Billiontoone during the 4th quarter worth $25,000. Wells Fargo & Company MN acquired a new position in shares of Billiontoone in the fourth quarter valued at about $76,000. Smartleaf Asset Management LLC bought a new position in Billiontoone during the fourth quarter worth about $80,000. T. Rowe Price Investment Management Inc. bought a new position in Billiontoone during the fourth quarter worth about $264,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Billiontoone in the 4th quarter worth about $347,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.